MaRS Innovation-U of T accelerator program among Canada’s best
The University of Toronto Early-Stage Technology accelerator program (UTEST) is now accepting applications for a third cohort until April 17, 2014.
Applicants must be current students or faculty at U of T, or have graduated within the last two years.
UTEST has just launched a new website with complete application information about the early-stage incubator and a link to the application form:
The 12-month program allows selected U of T affiliates to access office space, mentoring and $30,000 in funding, with opportunities to access follow-on funding from MaRS Innovation later on.
Minuum keyboard creators accelerate wearable device input technology development
Whirlscape, Inc., creators of the Minuum keyboard, closed an seed funding round of $500,000.
TORONTO, Canada (February 6, 2014) — Whirlscape Inc., creators of Minuum, “the little keyboard for big fingers,” have closed an investment seed round for just over $500,000 (USD). Y Combinator, FundersClub, BDC Venture Capital, and a dozen other prominent angel investors have contributed to the round.
Whirlscape’s plans for the capital involve innovating beyond its participation in Silicon Valley’s start-up accelerator Y Combinator. Whirlscape also aims to consolidate the success of its Minuum keyboard for Android touchscreen devices—available on Google Play—whose positive reviews have boosted sales since the New Year.
Since launching the Minuum keyboard in 2013, Whirlscape has grown to a dedicated team of 10 working to enable new ways to type, and to unify input methods across the rapidly emerging field of wearable and ubiquitous computing devices such as smart watches and Google Glass. Whirlscape has recently demonstrated the Minuum keyboard working on Samsung’s Galaxy Gear smart watch.
“Our vision for the future of hyper-personalized input devices involves letting you choose your companion device for its input capabilities,” said Will Walmsley, CEO of Whirlscape. “By simplifying the concept of the keyboard, we allow text entry to occur in places where it was previously unthinkable, removing barriers to communication. Your keyboard can now be anywhere you want it to be, out of the way, yet immediately accessible.”
Whirlscape, Inc. was in the first cohort of UTEST, the MaRS Innovation and University of Toronto accelerator program for early-stage technologies. UTEST is now accepting applications for their third cohort.
OtoSim™ device’s integration into medical students’ curriculum to help improve diagnosis accuracy by 44 per cent
A $200,000 donation led by Mr. Ralph Chiodo of Active Green + Ross will help establish a Student Training Fund in Otoscopy at U of T in partnership with OtoSim Inc.
TORONTO, ON (Feb. 5, 2014) — The University of Toronto (U of T) is creating a Student Training Fund in Otoscopy in partnership with OtoSim Inc., thanks to a $200,000 donation led by Mr. Ralph Chiodo, founder of Active Green + Ross. Other donors include some franchisees of Active Green + Ross and others among Chiodo’s friends and associates.
The Halldale Group, a publisher specializing in simulation and training information, covered this funding announcement.
Through the donation, undergraduate medical students will have access to better otoscopy training through the use of the OtoSim™ in their curriculum. Otoscopy, the diagnostic examination of the ear, is one of the most poorly-acquired medical skills in students, general practitioners and pediatricians, achieving a fifty per cent accuracy rate.
Ralph Chiodo’s donation allows OtoSim Inc. to provide 66 otoscopy training units, known as the OtoSim™,to U of T. The devices, which can be networked to facilitate mass training exercises, will help undergraduate medical students to be effectively trained to diagnose ear problems using an otoscope.
Watch how the OtoSim™ can be used in mass training exercises.Nearly 100 second-year medical students voluntarily attended the OtoSim™ training session to better prepare their otoscopy skills for the clinic.
“We are excited to be the first official OtoSim™ mass-training site and thank Mr. Ralph Chiodo for leading the charge on fundraising for this unique learning opportunity,” said Ian J. Witterick, professor and chair in U of T’s Department of Otolaryngology-Head & Neck Surgery.
“A clinical study demonstrated that with only a couple hours of group training, the accuracy of third-year medical students increased from 54 per cent to 78 per cent,” said Dr. Andrew Sinclair, OtoSim CEO and former senior director at MaRS Innovation. “Mr. Ralph Chiodo’s donation will help us to ensure that more medical students graduate with a much higher proficiency in this critical primary physical examination skill.”
The radio segment, called “Crowdfunding Science,” aired on January 25, 2014 and discussed the lack of funding researchers have access to for commercialization, making it harder to advance research that could be helping people in a variety of industries.
WaveCheck’s crowdfunding campaign is an example of how MaRS Innovation gets creative when traditional funding channels take too long or run dry, speeding up the commercialization process.
MI portfolio company actively seeking additional products for licensing and development
TORONTO and SAN DIEGO, Jan. 9, 2014 — A unique collaboration of life science leaders, including the Fight Against Cancer Innovation Trust, MaRS Innovation Ventures Trust and MaRS Phase II Investment Trust, have formed Triphase Accelerator Corporation, an oncology development accelerator.
Formed in 2010, Triphase Accelerator Corporation is a cancer-focused biotechnology development company that aims to reduce the time and expense between an investigational new drug application and “proof-of-concept” at Phase II.
Triphase, spun out of the Ontario Institute for Cancer Research (OICR), develops and advances late pre-clinical, Phase I or early Phase II potential products. Triphase and its founding investors are in a position to take advantage of the excellent research and development capabilities in the Toronto healthcare and innovation ecosystem.
The Fight Against Cancer Innovation Trust (FACIT), MaRS Innovation Ventures Trust, and MaRS Phase II Investment Trust, are all Toronto-based equity investors in Triphase.
After company formation, Triphase entered into a strategic relationship with Celgene Corporation. Through this arrangement, Celgene obtained rights of first refusal on the first three oncology products Triphase advances to clinical proof-of-concept (POC), plus a right of first negotiation on three more future oncology products which may be acquired by Triphase.
Technology developed by Dr. Stuart Berger at UHN is first project funded through partnership TORONTO, Dec. 11, 2013 - MaRS Innovation, a Centre of Excellence for Commercialization and Research, has announced…
MaRS Innovation’s commercialization process helps inventors move their transformational ideas from the lab bench to the market.
Johnson & Johnson Innovation and its affiliate Janssen Inc. in Canada announced new collaborations with two Canadian early-stage drug technology development centres, Montreal-based NEOMED and Toronto-based MaRS Innovation, to identify and advance promising bio/pharmaceutical technologies that have the potential to impact human health.
Through these collaborations, technical experts from the Johnson & Johnson Innovation Center in Boston, Massachusetts will work with NEOMED and MaRS Innovation to identify investment opportunities emerging from well-validated scientific research discoveries within their communities of academic institutions and biotechnology companies.
Council members include MI’s Raphael Hofstein and MI Board Chair Dr. Robert Bell
On November 20, the Government of Ontario launched the Ontario Health Innovation Council to support health innovation in Ontario. Dr. Raphael Hofstein, president and CEO of MaRS Innovation, was named to the council.
Members of the Ontario Health Innovation Council, including MaRS Innovation’s president and CEO Dr. Raphael Hofstein (third from left), pose after the initial announcement.
By becoming a member of the Council, Hofstein will assist in identifying evidence-based opportunities in Ontario’s healthcare space and advancing them into practice on a global scale.
Through the collaboration, MaRS Innovation and technical experts from the Johnson & Johnson Innovation Center in Boston, Massachusetts will jointly identify and fund high-potential opportunities emerging from well-validated scientific research discoveries within MaRS Innovation’s 16 member institutions, which include the University of Toronto and its affiliated teaching hospitals.
Dr. Raphael Hofstein, president and CEO of MaRS Innovation.
“We are looking forward to working with Johnson & Johnson Innovation,” said Dr. Raphael Hofstein, president and CEO, MaRS Innovation. “There are many high quality opportunities coming out of the Toronto research community, and these opportunities can benefit from our close collaboration.”
Through the agreement, Johnson & Johnson Innovation will provide funding over a three-year period to support promising individual projects based on joint due diligence, which will be leveraged with financial support from MaRS Innovation.
This program provides a simple mechanism to connect researchers with MI’s industry partners. The process and application form are intentionally brief to save researchers time and allow MI’s partners to review a wide range of remarkable technologies within the Toronto academic community in a short period of time.
Parimal Nathwani, vice-president, Life Sciences, MaRS Innovation.
“Many granting programs require an industry partner, but leave finding that partner to the researcher,” says Parimal Nathwani, vice-president of life sciences at MI. “Our Industrial Partnership Program completes that step for them. We also know researchers within our member institutions are incredibly busy, which is why we’ve adopted a streamlined process to save them time.”
The program is open to any researcher affiliated with our 16 member institutions working on technologies in:
The University of Toronto Early-Stage Technology accelerator program (UTEST) is now accepting applications for a third cohort until April 17, 2014.
